SINGAPORE GOVT ORPHAN DRUG ACT

3 February 1992

Under powers conferred by Section 9 of the Medicines Act, Singa-pore's Minister of Health has ruled that an orphan drug is a medicinal product which has been identified by any doctor or dentist as an appropriate remedy, with no effective substitute available for the treatment of any rare disease.

A rare disease is described as a life threatening and severely debilitating illness affecting less than 20,000 people. The lic-ensing authority may permit any person to import or supply the orphan drug without a product license, if that drug is to be used by a doctor or a dentist in the treatment of a patient under his care. Written records of all quantities imported and used will be required. No advertisement for orphan drugs will be permitted in publications circulated to hospitals, and the regulations regarding orphan drug status will cease to apply if the drug's use increases substantially in one year or if a product registration is granted by the authorities.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight